1 American Wellness Centre, Dhaka, Bangladesh.
2 The Center of Integrative Medicine, Texas, USA.
World Journal of Advanced Research and Reviews, 2025, 28(03), 1113-1126
Article DOI: 10.30574/wjarr.2025.28.3.4160
Received 01 November 2025; revised on 12 December 2025; accepted on 16 December 2025
Background: Stem cell–based therapy has gained increasing attention as a regenerative approach for neurodevelopmental and functional disorders. While global research supports the therapeutic potential of mesenchymal stem cells (MSCs), early clinical outcomes remain variable, and American cohort data are limited. This hybrid clinical‑trial study integrates empirical findings from 34 U.S. patients with a mechanistic scientific review to evaluate early functional and behavioral outcomes following MSC therapy.
Methods: Thirty‑four patients aged 4–30 years received MSC therapy using standardized cell quantities (15M, 50M, 100M) and four dosing intensities (Dose 1–4). Clinical outcomes were assessed across eight domains: digestion, toilet habits, sleep, hyperactivity, speech, communication, appetite, and overall improvement. Descriptive statistics, dose–response comparisons, and age‑group analyses were performed. Mechanistic interpretation was integrated using established MSC literature.
Results: Functional improvements appeared earlier and more frequently than developmental outcomes. Toilet habits improved in of patients, followed by hyperactivity reduction , digestion , and sleep . Speech and communication improved in each. Dose 3 demonstrated the highest improvement rate , and younger patients showed significantly greater responsiveness than adolescents or adults. Half the cohort exhibited no early improvement, consistent with expected MSC timelines.
Conclusion: Early findings suggest that MSC therapy may yield meaningful functional improvements in younger American patients, particularly at moderate‑to‑high dosing levels. The integration of empirical data with mechanistic insights highlights the therapeutic potential of MSCs while emphasizing the need for larger controlled studies in the United States. These findings should be interpreted cautiously due to the small sample size and early follow‑up window.
Mesenchymal Stem Cells; Autism; Neurodevelopment; Functional Outcomes; Regenerative Medicine; Clinical Trial; United States Cohort
Get Your e Certificate of Publication using below link
Preview Article PDF
M. Mojibul Haque, Abdullah Al Noman and Syeda Shayan Zehra. Real‑World Outcomes of Combined MSC Therapy and Functional Medicine in Autism: Early Functional and Behavioral Improvements. World Journal of Advanced Research and Reviews, 2025, 28(03), 1113-1126. Article DOI: https://doi.org/10.30574/wjarr.2025.28.3.4160.
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0